Excelsus Structural Solutions SPRL was created in March 2012 as a spin-off company of the Paul Scherrer Institute (PSI), the largest federal research center for natural and engineering sciences within Switzerland. Its main offices are located in Brussels (Belgium) whereas it operates primarily at the PSI synchrotron facility in Switzerland.


In February 2014, Excelsus Structural Solutions (Swiss) AG based in Switzerland was founded to ensure the prompt access of the ESS team to the synchrotron laboratories and facilitate the interaction with the local scientists. Since April 2016, Excelsus Structural Solutions (Swiss) AG is part of Switzerland Innovation PARK INNOVAARE. More on ESS (Swiss) AG transition to Switzerland Innovation PARK INNOVAARE. Interview to founder Dr Fabia Gozzo.


Excelsus Structural Solutions offers easy and affordable access to unique Synchrotron-based characterization tools developed at the Paul Scherrer Institute, to enhance the selection, development and manufacturing of high-quality (bio)pharmaceutical products.


Excelsus Structural Solutions Team of experienced synchrotron scientists with many years of experience in ab-initio structural solution, qualitative and quantitative phase analysis applied to pharmaceuticals will assist you in the definition of the best strategy to takle your specific problem, the conception of the appropriate experimental plan and the development and realization of it. Excelsus' Team will take care of sample preparation, definition of the most appropriate experimental conditions and protocol, data collection, reprocessing, analysis and interpretation and deliver to you a detailed experimental report that suits your specific needs, as defined by you.


Excelsus Structural Solutions team will make available to you the latest advanced Synchrotron X-Ray Powder Diffraction experimental data collection data analysis strategies that have made it possible the detection and quantification of traces of minority phases as low as 0.01% wt in organic pharmaceutical compounds. Level of Detection (LoD) and Level of Quantification (LoQ) as low as 0.01% wt have been recently demonstrated in organic pharmaceutical compounds when using unconventional beamline optics set up developed by Excelsus Team. MORE on 0.01% wt LoD.


The experience of highly qualified professionals in our team providing engineering and scientific services to the industry, while handling proprietary information with high confidentiality standards, is significantly greater than the years that we have been in business.


A network of scientists worldwide allows us to be uniquely positioned to broaden our services with the high standards of Excelsus.



KEYWORDS: Synchrotron X-Ray Powder Diffraction, Pharmaceuticals, Quantitative Phase Analysis, Qualitative Phase Anlaysis, Low Level of Detection, Low Level of Quantification

Dr. Fabia Gozzo, Excelsus' CEO at the 9th HECRA meeting
8th October 2018
Read more ›
Joint meeting: PPXRD-16 and SPS-XRPD-2
5th October 2018
Excelsus Structural Solutions has the pleasure to announce that the next edition of the SPS-XRPD workshop will be held together with the PPXRD-16 symposium in May 2019 in Switzerla ...
Read more ›
Dr. Pamela Whitfield was awarded the well-deserved ICDD Fellow award at the 2018 ICDD Spring Meetings.
26th March 2018
Congratulations to Pamela Whitfield who was awarded the ICDD (International Centre for Diffraction Data) Fellow award at the 2018 ICDD Spring Meetings. The designation of Fellow is ...
Read more ›
9th International HeCrA Conference
22nd March 2018
The CEO, Dr. Fabia Gozzo will be part of the Scientific Committee of the 9th International HeCrA Conference that will be held in University of Patras, Greece on 5-7 October 2018.
Read more ›
Our Customers
Privacy    Cookie Policy
realizzazione siti web